Merck Mercuriadis to exit Hipgnosis Songs Fund

Kardium Inc. raised $250m to support the launch of its Globe pulsed field system for treating atrial fibrillation. The latest fund raise brings the company’s total capital to $425m and was led by new investors, including Janus Henderson Investors and Eckuity Capital. Existing investors such as T. Rowe Price Investment Management and Durable Capital Partners LP also participated. CEO Kevin Chaplin said: “This funding enables us to move ahead with the commercial launch of the Globe system by expanding our manufacturing capabilities and building a strong commercial team.” 🚀 🔗 Get the full details: https://lnkd.in/ddsMBKQb 📰 Want the latest #MedTech updates straight to your inbox? Subscribe to our newsletter: https://lnkd.in/dvBDE7cN #MedicalDevices #MedicalEquipment #HealthTech #MedTechNews

Cumulus Neuroscience has closed a £3.5 million investment round led by a £1.5m investment from Whiterock 's Growth Capital Fund, alongside £1.25m from the Investment Fund for Northern Ireland's equity fund, run by @Clarendon Fund Managers, £0.3m from ACF Investors and £0.2m from Co Fund NI https://lnkd.in/gvgPfdfu

NATO Innovation Fund (NIF) announced their first biotech investment this week - U.K. deep tech start-up Portal Biotech advised by Covington & Burling LLP partner Ben Land-Maycock as well as associate Hannah Berry and special counsel Ross Evans raised $35 million in its Series A fundraise. Read Lucie Cruz’s story for The Lawyer here: https://lnkd.in/ewJ93KmN #natoinnovationfund #deeptech #seriesafundraise

Dresner Partners, an award-winning, FINRA-registered, middle-market investment bank and Mergers Alliance member firm, is pleased to announce that it advised New England Fertility Institute on its sale to CSG.Bio, in partnership with Corbel Capital Partners, a Los Angeles-based investment firm, and Weave Growth Partners, which acted as an independent sponsor.  Please click on the following link to read the full announcement. https://lnkd.in/gtD_aS_4

We recently advised THERME GROUP Group on forming a strategic joint venture with the private equity investment firm CVC. Upon closing of the transaction, Therme Group and CVC will become equal shareholders in Therme Horizon, a new holding company valued at over one billion euros. Deal team: Dr. Martina Ortner (lead), Dr. Bongertz Bastian, Dr. Annette Mutschler-Siebert M.Jur. (Oxford), Dr. Michael Kreft, Dr. Philipp Riedl, Dr. Christian Hullmann, Nils Neumann, Dr. Thomas Nietsch, and Dr. Ramona Ruf. Read more: https://ow.ly/BL6850WikPm

NEWS: a roster of law firms has taken the lead on NATO’s first biotech investment into Portal Biotech. Latham & Watkins and Covington & Burling LLP were joined by Simmons & Simmons and Wilson Sonsini Goodrich & Rosati on the AI-backed biotech’s Series A fundraise, led by the NATO Innovation Fund (NIF) and Earlybird Venture Capital. Read more about the fundraise and find out more about Portal Biotech in the article. https://lnkd.in/e-hPrwJT

Quantum-Si recently concluded a successful $50 million capital raise in collaboration with A.G.P./Alliance Global Partners, with transactional assistance from DLA Piper, including Larry Nishnick, Bianca LaCaille, Katerina Karaoglanova and Melody Lilazy. https://lnkd.in/g4khhZ9U

We are pleased to participate in Avalyn Pharma's $100M oversubscribed Series D funding round, which will support the advancement of the company’s inhaled therapies for pulmonary fibrosis.   Avalyn’s pipeline, including inhaled formulations of pirfenidone and nintedanib, has the potential to significantly improve treatment outcomes for patients with this life-threatening respiratory condition. Following Novo Holdings’ initial investment in 2017, this latest round underscores a long-term commitment to supporting transformative science into meaningful clinical impact across our life sciences portfolio.   Congratulations to CEO Lyn Baranowski and the Avalyn team! Learn more about Avalyn here: https://lnkd.in/enZ_6Yge #VentureInvestments #LifeSciences

Avalyn Pharma is tackling the challenges that have long limited treatment for patients with fibrotic lung diseases.   By reformulating oral antifibrotics into inhaled therapies, Avalyn is working to deliver higher drug concentrations directly to the lungs — while minimizing systemic side effects.   The company’s Series D raise marks a new phase of clinical progress, and we’re proud to support Avalyn as it brings this treatment closer to reality for patients who need better options. Read more: https://lnkd.in/eA2tqhbE

We are pleased to have advised SR One Capital Management and Novo Holdings on Avalyn Pharma’s $100 million oversubscribed Series D!  Avalyn Pharma is a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases. Learn more about the transaction at: https://lnkd.in/geT84Nmp